New neoadjuvant platform helps inform combo immunotherapy selection for cancers

By Samantha Black, PhD, ScienceBoard editor in chief

November 13, 2021 -- WASHINGTON, DC - In order to address some of the major challenges facing the immuno-oncology field, Dr. Tom Marron, PhD, has developed a platform to help researchers decide which drugs or combination of drugs to advance toward late-stage clinical trials. Marron spoke with ScienceBoard Editor in Chief, Samantha Black, PhD, onsite at the Society for Immunotherapy of Cancer's 2021 annual meeting.

Marron is the director of the Early Phase Trials Unit at the Icahn School of Medicine at Mount Sinai, where he and his team are developing a neoadjuvant platform that allows them to explore the immunotherapy space, specifically window of opportunity studies. These studies are conducted by administering an immunotherapy for a short period of time, such as two to six weeks prior to patient surgery. The small trials contain only 10-15 patients per cohort and are designed to rapidly accrue data to propel the field forward.

By comparing tissue pre and post-surgery, the team can determine what is happening in patients and what role the immunotherapy is playing in those changes. This is important, Marron noted, because it helps researchers understand the basic principle of how standard-of-care therapies and immunotherapies work and, importantly, what single or rare subset of myeloid cells are being affected by those therapies.

Video loading ...

Furthermore, Marron’s team is using high-resolution single-cell platforms, spatial transcriptomics platforms, and multiplexed immunohistochemistry tools to understand how drugs are affecting select subsets of cells involved in cancer and how those cells are perturbing the tumor microenvironment.

Ultimately, this will enable more intelligent decisions on which combination approaches to explore in larger populations, Marron said.

“We really don’t have enough patients to try every combination under the sun … in large phase II trials,” Marron explained. “We have to identify the most rational drugs to pursue in clinical trials so that we cannot spend the next 10-15 years for the next PD1 to be discovered and approved.”


Copyright © 2021 scienceboard.net
 

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:



Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences



Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.